Monsenso is ISO 13485 certified

Monsenso is ISO 13485 certified

Aug 21, 2020

Quality Policy and Standards

As a technology leader in mobile health (mHealth) solutions for mental health, Monsenso is ISO 13485 certified. ISO 13485 is the gold standard for medical device companies to ensure the quality, safety and efficacy of products in the medical device field. This certification ensures that the product in question, consistently meets customer requirements and regulatory requirements applicable to medical devices and other related services.

“Monsenso adheres to the highest security standards. Beyond, being ISO 13485 certified, Monsenso holds the ISO 27001 certification and class 1 CE mark.” says Thomas Lethenborg, CEO at Monsenso.

For additional information contact:
Jennifer Highland
Marketing and Communications Manager
Monsenso
+45 81 71 7713
highland@monsenso.com

GoGreen research project helps Monsenso enter new markets

GoGreen research project helps Monsenso enter new markets

Aug 7, 2020

GoGreen research project helps Monsenso expanding into new markets. Monsenso is pleased to announce that it is partnering with a pan-European consortium in the Go Green Routes research project supported by the Horizon 2020 programme. The consortium has been granted EUR 10.49 million from the EU to develop innovative solutions that foster mental health and well-being by optimising human-nature interactions for citizens. These innovations will increase the uptake and acceptability of nature-based solutions across the trial cities Burgas, Lahti, Limerick, Tallinn, Umea and Versailles.

Monsenso’s solution will be further developed and used to both encourage green nature-based choices and to monitor citizens’ mental health to help better understand the health impact of nature-based choices for people in cities. Monsenso’s share of the project contribution will be EUR 253.000.

“Participating in a project that combines nature-based solutions, green choices and mental health and well-being is very exciting for Monsenso. A lot of focus and investment is going into green solutions and technologies these years, and this could represent a great potential for us. Moreover, the project will expand our international network and help bring the Monsenso solution into new markets”. says Thomas Lethenborg, CEO of Monsenso. 

The project will start in September 2020 and is coordinated by the University of Limerick. The project run for four years and includes 40 partners across 18 countries, among others Mental Health Europe, King’s College London, Technical University Munich, Manchester Metropolitan University and universities in Tallinn, Aachen, Torino, Antwerpen, Versailles and Inland Norway as well as the trial cities.

“We envisage that GOGREEN ROUTES will translate cutting edge research into impactful solutions for cities health, mobility and ecology” says Dr Tadhg MacIntyre, lecturer in psychology at the University of Limerick and project lead coordinator.

This project is funded by the European Union’s Horizon 2020 framework programme under grant agreement No 869764.

To read the Danish version, click here.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Reference
GOGREEN ROUTES Project Outline, click here.

BOOK A DEMO
Monsenso receives ISO 27001 re-certification

Monsenso receives ISO 27001 re-certification

Jul 23, 2020

Copenhagen, Denmark – 23 July 2020. Monsenso recently received the ISO 27001 re-certification. This is the international standard that describes best practices for an information security management system (ISMS). The company had originally received the ISO 27001 certification in August 2017, and since the certification is valid for three years, the re-certification was due this summer.

Compliance with this certification validates that Monsenso has implemented comprehensive information security practices that protect its users and their information in accordance with internationally recognised standards.

The ISO 27001 standard ensures the secure management of customers’ information, intellectual property, and third party information by establishing methodologies and meeting key objectives for implementing information security.

Monsenso underwent an in-depth assessment by a third-party auditor to validate compliance with this standard. Maintenance of the certification requires an annual review and a three-year re-certification, giving Monsenso users confidence that their data is continuously protected under these standards.

With regards to obtaining the ISO 27001 certification, Thomas Lethenborg, CEO at Monsenso, commented “Data security is critical when dealing with medical information, and the ISO 27001 certification provides our users with the highest level of protection for their most sensitive data.”

For additional information, please contact:
Jennifer Highland
Marketing
Monsenso
+45 30 25 15 26
marketing@monsenso.com

Research project HedaX aims to develop a new platform to securely handle health data

Research project HedaX aims to develop a new platform to securely handle health data

Jul 3, 2020

Copenhagen Demark – 22 June 2020. The Research Project HedaX received EUR 16 million from the Danish Innovation Fund to develop a digital platform that can securely collect and exchange health data. This tool will provide researchers with the basis to offer better, personalised medicine.

In the current world situation, the proliferation of a new virus has had fatal consequences for society. However, the spread of infection can be curbed by collecting and exchanging data; this data exchange needs to take place without compromising an individual’s privacy. The Research Project HedaX aims to develop a digital solution that collects and exchanges personal health data anonymously and securely.

 

THE DANISH RESEARCH PROJECT HEDAX HAS A SOLUTION

The Research Project HedaX project will initially test the solution in two pilot projects that involve 1,000 cancer patients and 1,000 people with bipolar disorder. The goal is to use this new health data to gain insight into how the treatment is helping patients, and to demonstrate that sharing personal health data can help develop better-personalised care.

The Research Project HedaX involves ten public and private partners that will work together to develop a platform that ensures health data is securely collected and exchanged between individuals, healthcare professionals, and researchers.

The data collected by the solution would include an individual’s medical history, medication compliance, and personal sensor data, which is the data collected by most fitness apps.

The analysis of this data should provide a basis for better and cheaper treatment in the form of personalised medicine.  The platform should also be used to monitor the spread of an infection confidentially, so that it is possible to identify where the infected individuals are located, without knowing who they are.

The newly developed platform should include the latest and most secure data encryption from various sources, such as the individual’s mobile phone, to the Social Security Registry and government’s databases.

Individuals should be able to get an overview and insight into the data that is being used, the entity using the data, and its purpose.

The Monsenso mHealth solution will be used to collect objective and subjective data from 1,000 individuals with bipolar disorder. The data will be anonymised and incorporated to the Registry data and EMR data to provide a new foundation for deep phenotyping, personalised medicine and overall understanding of real-life drug effectiveness.

“During the past five years, the Monsenso mHealth solution has been used in different research projects around the world to securely collect and share data between individuals with a mental illness and their healthcare professional. The scope of the project is rather familiar to us, and we are looking forward to participating in this project and helping individuals maintain their privacy while their data is safely collected and used to improve future treatments,” says Thomas Lethenborg, CEO of Monsenso.

 

The HedaX partners:

Secata is a pioneer in the commercial application of advanced encryption for data sharing. Their technology is based on more than 20 years of groundbreaking research in secure multiparty computation.

The Data for Good Foundation is a newly established foundation with non-profit purposes, based on GDPR legislation, that helps individuals share and retain control over their data.

DataFair is an entrepreneurial company with a particular focus on data-driven innovation and personalised medicine based on Denmark’s reliable health data.

The Alexandra Institute works with applied research in the field of digitisation and has helped develop encryption technology within the health sector.

The Danish Cancer Society is Denmark’s largest patient organisation.

Lundbeck is a Danish pharmaceutical company working on the development of pharmaceuticals within psychiatry and neurology.

Monsenso is a Danish company that develops mobile health solutions that help individuals collect information on their mobile phone to use it for prevention and treatment.

The Danish Capital Healthcare Region (Region H) offers Monsenso’s solution to patients within psychiatry.

DPO Management advises on secure and confidential sharing of data with a focus on GDPR rules.

Clinical Epidemiological Department at Aarhus University works with analysis of health data.

To read the Danish version, click here. 

For additional information contact:

Jennifer Highland
Marketing Consultant
marketing@monsenso.com
Monsenso

Monsenso’s IPO offering was oversubscribed by 238%

Monsenso’s IPO offering was oversubscribed by 238%

Jun 3, 2020

Copenhagen Demark – 3 June 2020. Monsenso A/S today announced the result of the new share offering in connection with the IPO on Nasdaq First North Growth Market Denmark.

Monsenso’s IPO offering was oversubscribed by 238%, which means that the company offer of DKK 16-20 million new shares was extremely well received by both professional and private investors, which together have subscribed for DKK 47,504,123, corresponding to the maximum offering.

The subscription period closed on 29 May 2020 at 23:59 hrs. CEST time. The company’s offering of up to 3,773,585 shares, at a price of DKK 5.30 per share has come to an end and will provide the company with gross proceeds of DKK 20 million and result in a market cap of DKK 70.04 million.

Monsenso received subscriptions from 2,219 investors for a total of 8,963,042 shares corresponding to the offering being oversubscribed by a total of 238%.

The first trading day on Nasdaq First North Growth Market Denmark is expected to be on 10 June 2020.

CEO Thomas Lethenborg, Monsenso said:

“The IPO offering was very well received by professional and private investors, including great participation in our online investor meetings. We have now received the necessary funding to strengthen our sales efforts, customer support, and to further develop our mHealth solution for mental health. We now have to live up to the trust and expectations coming from our 2,219 new shareholders. We look forward to being a listed company and welcoming the continued support from our many new shareholders.”

Summary of the Offer:

  • Monsenso issued 3,773,585 new shares at a subscription price of DKK 5.30 per share, which gives gross proceeds of DKK 20.0 million
  • Based on the offer price, Monsenso’s market cap is now DKK 70.05 million
  • Free float (the proportion of the share capital owned by the new shareholders) is 27.05%
  • Due to the great interest in the offering, all orders up to and including DKK 150,000 have been allocated 720 shares plus 20% of the number of shares subscribed for in addition to the 720 shares
  • All orders over DKK 150,000 have been reduced individually based on the company’s assessment
  • All pre-offering subscribers have received a full allocation.

For additional information contact:

Thomas Lethenborg
CEO Monsenso
lethenborg@monsenso.com

Interview with Monsenso’s Chairman Jukka Pertola

Interview with Monsenso’s Chairman Jukka Pertola

May 12, 2020

Q&A with Monsenso’s Chairman Jukka Pertola

Describe your role in the company
“I joined the company because I have an understanding of IT and software and long-standing experience of working on different boards. When a small company like Monsenso is going public, all the governance structures need to be in place, and that is where I come in. I have previously taken GomSpace to First North in Stockholm. When I joined GomSpace as Chairman of the Board, there were 30 employees, and today they are 150 with a sizeable turnover.”

What is your most important contribution as Chairman of the Board?
“My most important contribution as the Chairman of the Board will be to establish a solid governance structure for when the company goes public. It is my goal to ensure that Monsenso is successfully noted on Nasdaq First North Growth Market this summer.”

 Why did you choose Monsenso?
“Monsenso is an exciting, small company that works within a field where the demand for smart IT-solutions is enormous. The company has a clear positive impact and a very well-defined purpose, and I am proud of the of it, that is why I chose to become the chairman.

Besides, mental health problems are widespread, and according to many publications, hospitals lack the capacity and resources to treat people with mental health problems adequately.

Healthcare professionals need new and effective tools to improve patient-clinician communication and to optimize treatment, and that is a mission I am happy to help support. The pending stock exchange listing will raise capital to the future growth and Monsenso has a significant global potential with it’s certified mobile health solution.”

Can you say a few words about your relationship with Monsenso’s  CEO and CSO
“I know Monsenso’s CEO, Thomas Lethenborg from Siemens, where we worked together closely. Thomas is a competent and experienced leader with a comprehensive understanding of IT and technology, including software services. I believe he is right for Monsenso, and I am looking forward to taking the company public this summer.

I also have a deep trust in Jakob Bardram, who is a respected professor at DTU, and the CTO of Monsenso. Jakob and I have also worked closely, during my time at Siemens. Jakob combines technical knowledge with a deep understanding of mental healthcare, ensuring that Monsenso’s mHealth solution is research-based and certified.”

Why did Monsenso decide to go public during the Corona crisis?
“It is a very uncertain market at the moment, and many companies are postponing their listings. However, since physical contact and doctor’s appointments are minimal at the moment,  all types of mobile health solutions are in high demand, and the Monsenso mHealth solution is a fantastic tool for mental healthcare professionals. Furthermore, when the world is becoming more uncertain and volatile, and we are subject to being somehow isolated in our homes, the need for mental health solutions like the one offered by Monsenso will increase. That is why we are maintaining our plans of going public in June.”

To read more about Monsenso’s intention to go public click on this link: https://www.monsenso.com/monsenso-is-ready-for-the-stock-exchange-after-continuous-growth/

For additional information contact:

Jennifer Highland
Marketing, Monsenso
marketing@monsenso.com